NCT01703572 - A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Relapsed or Refractory Lymphoid Malignancies

Interventions

DRUG

OMP-52M51

Trial Locations (10)

Cornell University Division of Hematology and Medical Oncology, New York

University of Rochester Medical Center, Rochester

Duke Cancer Institute, Durham

UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville

Sara Cannon Research Institute, Nashville

University of Nebraska Medical Center, Omaha

University of Colorado Hospital, Anschutz Cancer Pavilion, Aurora

UC San Diego Moores Cancer Center, La Jolla

NYU Clinical Cancer Center, New York

University of Nebraska Medical Center, Omaha